Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

120.88
-0.3600-0.30%
Post-market: 120.880.00000.00%19:30 EDT
Volume:21.60K
Turnover:2.61M
Market Cap:545.17M
PE:6.27
High:121.66
Open:121.66
Low:120.55
Close:121.24
52wk High:131.68
52wk Low:92.10
Shares:4.51M
Float Shares:4.51M
Volume Ratio:0.46
T/O Rate:0.48%
Dividend:1.11
Dividend Rate:0.92%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.64
PE(LYR):5.56

Loading ...

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Yesterday

Abbott Laboratories (ABT) Launches SimpleScreen CRC As Fair Value Debate Heats Up

Simply Wall St.
·
Yesterday

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

AbbVie Joins US Government Pilot to Test Drug Discount Rebates

Reuters
·
Yesterday

Amgen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Yesterday

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Abbvie-from Jan 1, 2027, Covered Entities to Submit Claims to GET 340B Pricing Through Beacon on 340B-Eligible Dispenses of Imbruvica, Linzess,Vraylar

THOMSON REUTERS
·
Yesterday

Abbvie - Approved to Participate in Federal 340B Rebate Model Pilot Program

THOMSON REUTERS
·
Yesterday

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Yesterday

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Dow Jones
·
Yesterday

Bayer to invest $2.2B in new manufacturing site in New Albany, Ohio

TIPRANKS
·
Yesterday

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Yesterday

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Yesterday

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Yesterday

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Yesterday

Amgen’s Evolocumab Study Signals Quiet Efficiency Gains for Cholesterol Franchise

TIPRANKS
·
Yesterday

AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for Investors

TIPRANKS
·
Yesterday

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

TIPRANKS
·
Oct 02

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

Reuters
·
Oct 02